



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 72264

Title: Hepatic perivascular epithelioid cell tumor: A case report and review of literature

Provenance and peer review: Unsolicited manuscript; externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05225141

Position: Peer Reviewer

Academic degree: DVM, PhD

Professional title: Doctor

Reviewer’s Country/Territory: United States

Author’s Country/Territory: China

Manuscript submission date: 2021-10-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-10-10 12:08

Reviewer performed review: 2021-10-16 19:53

Review time: 6 Days and 7 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This case reported a mesenchymal tumor, perivascular epithelioid cell tumor (PEComa), which is a rare tumor in the liver, specifically for the malignant case. In addition, the authors also found that transarterial embolization (TAE) in combination with sorafenib treatment is a safe and feasible strategy to shrink the tumor and make it applicable to surgical removal. Overall, the results and report are suitable to publish in this journal. However, some revision is necessary to enhance the quality of this article. Please check the formats of author names and Departments. Figure 1, use a circle or arrow to point the tumor out; Figure 2, the images are too dim, clear pictures are needed, especially for Figure 2 A; Figure 4, similar to Figure 1, pointing out the tumor to clearly show their difference. The time point of when four TAEs were performed. Figure 5, labeling the difference between two images. Grammar errors: The patient was followed up with for > The patient was followed up for; tumor.Based > tumor. Based; The appearance of symptoms may be related to increase in tumor size > The appearance of symptoms may be related to an increase in tumor size; which have different degree of differentiation > which have different degrees of differentiation; A: Positive staining of giant tumor in right lobe of liver before treatment > A: Positive staining of giant tumor in right lobe of the liver before treatment. The full name of TAE should be mentioned in the abstract. Primary hepatic PEComa is rare [2], > [2],



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 72264

Title: Hepatic perivascular epithelioid cell tumor: A case report and review of literature

Provenance and peer review: Unsolicited manuscript; externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05923483

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2021-10-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-10-20 03:23

Reviewer performed review: 2021-10-27 02:34

Review time: 6 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Perivascular epithelioid cell tumor (PEComa) is an uncommon tumor of mesenchymal origin. Cases of PEComa in the liver are extremely rare. This article shows an interesting case. Because of the large tumor size, TAE combined with sorafenib is a safe and feasible adjuvant treatment method when surgery cannot be performed. Overall, this manuscript is suitable for publishing in this journal after some necessary revision to improve the quality. 1. Sharper, larger resolution, and higher quality images should be given in Figure 2. 2. On page 5, line 119. "Based on the characteristics of the tumor and a lack of sensitive chemotherapeutic drugs, the treatment modality of TAE was chosen instead of transcatheter arterial chemoembolization (TACE) as the hypoxia caused by TAE could potentially upregulate angiogenic factors and stimulate the proliferation of residual tumor cells, leading to tumor survival and recurrence." There is confusion in the logic of this sentence, and please revise it to make it more straightforward.